Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer

Abstract Metastatic triple-negative breast cancer (mTNBC) is a heterogeneous disease with a poor prognosis. Individualized survival prediction tool is useful for this population. We constructed the predicted nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) using the dat...

Full description

Bibliographic Details
Main Authors: Mao-Shan Chen, Peng-Cheng Liu, Jin-Zhi Yi, Li Xu, Tao He, Hao Wu, Ji-Qiao Yang, Qing Lv
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-18727-2
_version_ 1798004269439254528
author Mao-Shan Chen
Peng-Cheng Liu
Jin-Zhi Yi
Li Xu
Tao He
Hao Wu
Ji-Qiao Yang
Qing Lv
author_facet Mao-Shan Chen
Peng-Cheng Liu
Jin-Zhi Yi
Li Xu
Tao He
Hao Wu
Ji-Qiao Yang
Qing Lv
author_sort Mao-Shan Chen
collection DOAJ
description Abstract Metastatic triple-negative breast cancer (mTNBC) is a heterogeneous disease with a poor prognosis. Individualized survival prediction tool is useful for this population. We constructed the predicted nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) using the data identified from the Surveillance, Epidemiology, and End Results database. The Concordance index (C-index), the area under the time-dependent receiver operating characteristic curve (AUC) and the calibration curves were used for the discrimination and calibration of the nomograms in the training and validation cohorts, respectively. 1962 mTNBC patients with a median follow-up was 13 months (interquartile range, 6–22 months), 1639 (83.54%) cases died of any cause, and 1469 (74.87%) died of breast cancer. Nine and ten independent prognostic factors for BCSS and OS were identified and integrated to construct the nomograms, respectively. The C-indexes of the nomogram for BCSS and OS were 0.694 (95% CI 0.676–0.712) and 0.699 (95% CI 0.679–0.715) in the training cohort, and 0.699 (95% CI 0.686–0.712) and 0.697 (95% CI 0.679–0.715) in the validation cohort, respectively. The AUC values of the nomograms to predict 1-, 2-, and 3-year BCSS and OS indicated good specificity and sensitivity in internal and external validation. The calibration curves showed a favorable consistency between the actual and the predicted survival in the training and validation cohorts. These nomograms based on clinicopathological factors and treatment could reliably predict the survival of mTNBC patient. This may be a useful tool for individualized healthcare decision-making.
first_indexed 2024-04-11T12:22:00Z
format Article
id doaj.art-ddd0fd3a684042f198a2bdee5ccb9aa1
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-11T12:22:00Z
publishDate 2022-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-ddd0fd3a684042f198a2bdee5ccb9aa12022-12-22T04:24:05ZengNature PortfolioScientific Reports2045-23222022-08-0112111110.1038/s41598-022-18727-2Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancerMao-Shan Chen0Peng-Cheng Liu1Jin-Zhi Yi2Li Xu3Tao He4Hao Wu5Ji-Qiao Yang6Qing Lv7Department of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityDepartment of Breast Surgery, West China Hospital of Sichuan UniversityAbstract Metastatic triple-negative breast cancer (mTNBC) is a heterogeneous disease with a poor prognosis. Individualized survival prediction tool is useful for this population. We constructed the predicted nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) using the data identified from the Surveillance, Epidemiology, and End Results database. The Concordance index (C-index), the area under the time-dependent receiver operating characteristic curve (AUC) and the calibration curves were used for the discrimination and calibration of the nomograms in the training and validation cohorts, respectively. 1962 mTNBC patients with a median follow-up was 13 months (interquartile range, 6–22 months), 1639 (83.54%) cases died of any cause, and 1469 (74.87%) died of breast cancer. Nine and ten independent prognostic factors for BCSS and OS were identified and integrated to construct the nomograms, respectively. The C-indexes of the nomogram for BCSS and OS were 0.694 (95% CI 0.676–0.712) and 0.699 (95% CI 0.679–0.715) in the training cohort, and 0.699 (95% CI 0.686–0.712) and 0.697 (95% CI 0.679–0.715) in the validation cohort, respectively. The AUC values of the nomograms to predict 1-, 2-, and 3-year BCSS and OS indicated good specificity and sensitivity in internal and external validation. The calibration curves showed a favorable consistency between the actual and the predicted survival in the training and validation cohorts. These nomograms based on clinicopathological factors and treatment could reliably predict the survival of mTNBC patient. This may be a useful tool for individualized healthcare decision-making.https://doi.org/10.1038/s41598-022-18727-2
spellingShingle Mao-Shan Chen
Peng-Cheng Liu
Jin-Zhi Yi
Li Xu
Tao He
Hao Wu
Ji-Qiao Yang
Qing Lv
Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
Scientific Reports
title Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
title_full Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
title_fullStr Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
title_full_unstemmed Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
title_short Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
title_sort development and validation of nomograms for predicting survival in patients with de novo metastatic triple negative breast cancer
url https://doi.org/10.1038/s41598-022-18727-2
work_keys_str_mv AT maoshanchen developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT pengchengliu developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT jinzhiyi developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT lixu developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT taohe developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT haowu developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT jiqiaoyang developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer
AT qinglv developmentandvalidationofnomogramsforpredictingsurvivalinpatientswithdenovometastatictriplenegativebreastcancer